New York - A recent in vitro study uncovered specific details of the immunoregulatory agent, fontolizumab (HuZAFTM), showing the biologic modifier as able to block transcripts induced by the naturally occurring human protein, interferon-gamma, said Jules Cohen, M.D., at the International Psoriasis Symposium.
